Talstad I, Kjelby K
Am J Clin Pathol. 1985 Sep;84(3):317-22. doi: 10.1093/ajcp/84.3.317.
The ideal method of heparinization should achieve therapeutic concentrations (0.2-0.5 IU/mL) in the artificial kidney and the least possible amount of heparin in the patient. Total heparinization using a bolus dose (8400 IU) followed by continuous infusion of heparin (20 IU/min), initially showed 1.4-2.4 IU/mL in the artificial kidney and the patient, but unpredictable slopes. High-dose regional heparinization (120-144 IU/min) and neutralization showed sustained heparin concentrations (0.4-0.6 IU/mL) in the artificial kidney, and less than 0.2 IU/mL in the patient. Low-dose regional heparinization (25 IU/min) initially showed 0.25-0.45 IU/mL in the artificial kidney, but unpredictable slopes in the patient. Low-dose regional heparinization (25 IU/min) and neutralization showed sustained heparin concentrations (0.15-0.35 IU/mL) in the artificial kidney and less than 0.15 IU/mL in the patient.
理想的肝素化方法应在人工肾中达到治疗浓度(0.2 - 0.5国际单位/毫升),且患者体内的肝素量尽可能少。采用大剂量推注(8400国际单位)随后持续输注肝素(20国际单位/分钟)的全量肝素化,最初在人工肾和患者体内显示为1.4 - 2.4国际单位/毫升,但斜率不可预测。高剂量局部肝素化(120 - 144国际单位/分钟)及中和作用在人工肾中显示肝素浓度持续保持在(0.4 - 0.6国际单位/毫升),而在患者体内则低于0.2国际单位/毫升。低剂量局部肝素化(25国际单位/分钟)最初在人工肾中显示为0.25 - 0.45国际单位/毫升,但在患者体内斜率不可预测。低剂量局部肝素化(25国际单位/分钟)及中和作用在人工肾中显示肝素浓度持续保持在(0.15 - 0.35国际单位/毫升),而在患者体内则低于0.15国际单位/毫升。